$770M Thyroid Cancer Drugs Market Insights, 2015-2030

DUBLIN, March 4, 2020 /PRNewswire/ -- The "Thyroid Cancer Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

The global thyroid cancer drugs market was valued at about $0.4 billion in 2018 and is expected to grow to $0.77 billion at a CAGR of 17.7% through 2022. Major players in the market are Mylan Pharmaceuticals, Alara Pharmaceutical Corporation, Bristol Myers Co, Teva Parenteral Medicines, and Jerome Stevens Pharmaceuticals.

North America was the largest region in the thyroid cancer drugs market in 2018, followed by Europe. The thyroid cancer drugs market in Asia-Pacific is forecasted to register the highest CAGR during 2018-2023.

Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market. According to the American Cancer Society, women are three times more likely to develop thyroid cancer than men. Thyroid cancer is rising at a fast pace and it is estimated that 52,070 new cases of thyroid cancer will be found in the USA in 2019 and an estimated 2,170 deaths will occur because of the disease. The increase in thyroid cancer can be attributed to exposure to radiation, family history of goiter and some hereditary syndromes.

Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market. Targeted therapies target cancer specific genes, proteins and tissues that promote cancer growth and survival. Targeted therapies are increasingly being used to treat thyroid cancer as thyroid hormone-based treatments including radioactive iodine therapy are not effective against these cancers. For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC). As patients increasingly use targeted therapies for treatment, demand for thyroid cancer drugs is decreasing, affecting market growth.

Combination drugs are increasingly being used in the treatment of thyroid cancer as they are more effective and help prevent cancer progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For instance, in 2018, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Manufacturers of thyroid cancer drugs are governed by regulatory authorities such as the Food and Drug Administration in the USA. For instance, off-label usage of FDA approved drugs for the treatment of cancer requires approval from the FDA. Manufacturers are required to submit a supplemental marketing application called sNDA( Supplemental New Drug Application) to the FDA that approves the drug for prescription.

In February 2019, Eli Lilly and Company acquired Loxo Oncology, Inc.for $8 Billion. The acquisition provides Eli Lilly access to a pipeline of investigational medicines like RET inhibitors which are used in thyroid cancer treatment. Loxo Oncology was established in 2013 and is located in Stamford, USA.

Key Topics Covered

1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Size and Growth
3.1. Global Thyroid Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers of the Market
3.1.2. Restraints on the Market
3.2. Global Thyroid Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers of the Market
3.2.2. Restraints on the Market

4. Thyroid Cancer Drugs Market Segmentation
4.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

• Ipilimumab
• Cabozantinib-S-Malate
• Caprelsa (Vandetanib)
• Doxorubicin Hydrochloride
• Lenvatinib Mesylate
• Nivolumab
• Vandetanib
• Others

4.2. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

• Hospitals
• Oncology Clinics
• Research Organizations
• Others

4.3. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

• Radioiodine Ablation
• Thyroid Stimulating Hormone (THS) Suppression
• Chemotherapy
• Targeted Multikinase Therapy
• Others

5. Thyroid Cancer Drugs Market Regional and Country Analysis
5.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

Companies Mentioned

• Abbott Laboratories
• Alara Pharmaceutical Corporation
• APP Pharmaceuticals LLC.
• Astrazeneca plc
• Azaya Therapeutics
• Baxter International Inc.
• Bayer
• Bio-Path Holdings
• Bionomics
• Biovista
• Bristol Myers Co.
• Eisai
• Exelixis Inc.
• GlaxoSmithKline plc
• Jerome Stevens Pharmaceuticals Inc.
• Mylan Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company
• Teva Parenteral Medicines Inc.
• Vascular Biogenics

For more information about this report visit https://www.researchandmarkets.com/r/hi0dv3

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com